Last mentioned: Feb 25, 2026
Zevia and Chemed both reported fourth-quarter revenue that fell short of analyst expectations, leading to significant stock price declines. While Zevia managed a slight EPS beat, Chemed saw a dramatic 14.7% plunge as investors prioritized top-line growth and guidance over narrow margin improvements.
Beverage maker Zevia and service conglomerate Chemed both reported fourth-quarter 2025 revenue that fell short of Wall Street expectations. The misses triggered significant sell-offs, with Chemed shares diving nearly 15% as investors recalibrate growth expectations for 2026.
Chemed Corporation and Zevia PBC both reported fourth-quarter 2025 revenue figures that fell short of Wall Street expectations, triggering significant stock price declines. Chemed, a major player in the hospice care sector through VITAS, saw its shares plummet 14.7% as investors reacted to the top-line disappointment.